Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (175)
  • Open Access

    REVIEW

    Receptor Reexpression after Hypermethylation: Novel Targets for Inhibitors and Antibody-Drug Conjugates in ALL

    Christoph Rehbach1, Patrick A. H. Ehm2,*

    BIOCELL, Vol.50, No.5, 2026, DOI:10.32604/biocell.2026.075170 - 13 May 2026

    Abstract Despite improved overall prognosis, the treatment of high-risk acute lymphoblastic leukemia (ALL) remains challenging due to the toxicity of intensive polychemotherapy and the limited efficacy of antibody-targeted therapies beyond cluster of differentiation 20 and 22 (CD20 and CD22). ALL is driven not only by genetic alterations but also by profound epigenetic dysregulation, including promoter hypermethylation that also silences surface receptor genes. This epigenetic repression can reduce the efficacy of targeted immunotherapies and contribute to relapse. Epigenetic reprogramming with DNA demethylating agents (e.g., decitabine) has the potential to restore the expression of key B cell receptors… More >

  • Open Access

    ARTICLE

    Bladder cancer patients hospitalized in a medicine ward including three fuo cases following bacillus calmette-guérin immunotherapy

    George Liatsos*, Kalliopi Zioutou, Konstantinos Avramidis, Konstantinos Vamvakaris, Maria Potamiti-Komi, Dimitrios Vassilopoulos

    Canadian Journal of Urology, Vol.33, No.2, pp. 349-360, 2026, DOI:10.32604/cju.2026.072711 - 20 April 2026

    Abstract Objectives: Bladder cancer (BC) is a prevalent malignancy with evolving treatment strategies and an increasingly aging patient population, resulting in a growing and complex burden of hospitalizations that extends beyond urological care and remains insufficiently characterized in real-world Internal Medicine settings. This study aimed to analyze the clinical data and outcomes for patients with BC admitted to the medicine ward. Additionally, this research presents three cases of fever of unknown origin, which all exhibited identical clinical and laboratory findings but ultimately resulted in different disease diagnoses. Methods: This retrospective case-series study included all adult patients… More >

  • Open Access

    ARTICLE

    Co-expression of CCR7 and H3K9me3 identifies aggressive B-cell lymphoma with bone marrow infiltration and poor prognosis

    Jiawen Chen1,#, Zelin Liu1,#, Keke Huang1, Jinlan Li1, Yajie Zhang1, Dandan Chen1, Yanjie Ruan2, Ying Pan1, Furun An1, Yang Wan1,*, Jiyu Wang1,3,*, Qianshan Tao1,*

    European Cytokine Network, Vol.37, No.1, pp. 25-39, 2026, DOI:10.32604/ecn.2026.077875 - 13 April 2026

    Abstract Objectives: B-cell lymphoma exhibits significant clinical heterogeneity, necessitating improved biomarkers for risk stratification. C-C chemokine receptor 7 (CCR7) and trimethylation of histone H3 lysine 9 (H3K9me3) are implicated in cellular senescence and tumor invasion. While the clinical significance of their co-expression in lymphomagenesis remains unclear. This study aims to define the expression profiles of CCR7 and H3K9me3 in B-cell lymphoma, explore their correlation with aggressive clinical indicators, and evaluate their combined prognostic value. Methods: The expression of CCR7 and H3K9me3 in tumor tissues from B-cell lymphoma patients was analyzed by immunohistochemical (IHC) double-staining. The mechanistic… More >

  • Open Access

    ARTICLE

    Pre-Treatment BOC Expression as an Indicator of Lymphovascular Invasion and In Vitro Chemotherapeutic Response in Upper Tract Urothelial Carcinoma

    Yin-Lun Chang1,2, Hao-Lun Luo1, Jei-Ming Peng3,*, Chang-Chun Hsiao2,*

    Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070837 - 23 March 2026

    Abstract Background: Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with high recurrence rates. Lymphovascular invasion (LVI) predicts a poor prognosis, yet its molecular drivers remain unclear. BOC cell adhesion-associated, oncogene-regulated (BOC, also known as Brother of CDO [Cell adhesion molecule-Related/Down-regulated by Oncogenes]), a hedgehog-related cell surface receptor, may serve as a biomarker for tumor progression and chemotherapy response. The study aimed to investigate the role of BOC in UTUC and its potential to predict LVI and chemotherapy response. Methods: Sequencing (RNA-seq) of 10 stage III UTUC, treatment-naïve, fresh tissue samples identified BOC as a… More >

  • Open Access

    ARTICLE

    PSMA PET/CT-guided pelvic lymph node dissection in patients with unfavorable intermediate- or high-risk prostate cancer

    Eva Donck1,*, Sofie Verbeke2, Pieter De Visschere3, Valérie Fonteyne4, Charles Van Praet1, Kathia De Man5, Nicolaas Lumen1

    Canadian Journal of Urology, Vol.33, No.1, pp. 83-92, 2026, DOI:10.32604/cju.2025.068589 - 28 February 2026

    Abstract Objectives: PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography) offers improved accuracy in detecting lymph node invasion (LNI) in prostate cancer (PC) patients, potentially reducing the need for extended pelvic lymph node dissection (ePLND). This study aims to evaluate a patient-tailored care pathway in which ePLND is performed only in patients with unfavorable intermediate- or high-risk PC who are deemed at risk for LNI based on PSMA PET/CT findings. Methods: In this interventional cohort study, 81 patients were managed according to the new care pathway. ePLND was omitted in cases of negative PSMA PET/CT… More >

  • Open Access

    ARTICLE

    Association of tertiary lymphoid structures and benign lymphoepithelial lesions in NIH-category IV prostatitis: pathophysiological correlations

    Dorian Dikov1, Maria Koleva2,*, Kiril Simitchiev3, Anelia Bivolarska4, Albena Fakirova5, Victoria Sarafian6,7

    Canadian Journal of Urology, Vol.33, No.1, pp. 125-134, 2026, DOI:10.32604/cju.2025.068575 - 28 February 2026

    Abstract Background: Chronic inflammation is closely associated with the most common and socially significant prostate conditions, including benign prostatic hyperplasia (BPH), prostate cancer (PCa), and prostatitis syndromes. NIH-category IV prostatitis (histologic prostatitis, HP) is defined as asymptomatic chronic inflammation of the prostate. The presence of lymphoid follicles, referred to as tertiary lymphoid structures (TLSs), along with benign lympho-epithelial lesions (BLELs), is among the key histological indicators of immune inflammation and can be assessed relatively easily. This study aimed to quantitatively assess TLSs and BLELs, as well as their relationship with the severity of HP. Methods: We… More >

  • Open Access

    REVIEW

    Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma

    Yuriy Mayasin1,*, Maria Osinnikova2, Daria Osadchaya1, Victoria Dmitrienko1, Anna Gorodilova1, Chulpan Kharisova1, Kristina Kitaeva1, Valeria Solovyeva1, Albert Rizvanov1,3

    Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.073008 - 24 February 2026

    Abstract Classical Hodgkin lymphoma (cHL) is characterized by rare Hodgkin/Reed-Sternberg (HRS) tumor cells that uniformly express cluster of differentiation (CD)30 molecules and orchestrate an immunosuppressive tumor microenvironment, making CD30 an attractive and selective therapeutic target. We summarize the biological rationale for CD30 as a therapeutic target and the preclinical and clinical evidence across major platforms: antibody-drug conjugates (brentuximab vedotin), monoclonal antibodies (including acimtamig and its combinations with Natural Killer cells), second- and third-generation chimeric antigen receptor (CAR)-T cells, and alternative modalities. Particular attention is given to standardized response assessment (IWG, Lugano, RECIL criteria), which enables appropriate… More >

  • Open Access

    VIEWPOINT

    Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin’s Lymphomas: A Viewpoint

    Guido Carloni, Monica Rinaldi*

    Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.071847 - 24 February 2026

    Abstract Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are increasingly recognized as significant etiological factors in the pathogenesis of B-cell non-Hodgkin’s lymphomas (B-NHLs). Epidemiological and molecular studies have demonstrated a consistent association between chronic viral infection and B-NHLs. Multiple pathogenic mechanisms have been implicated in lymphomagenesis, both direct and indirect, including chronic antigenic stimulation, direct infection of B cells, and viral protein–mediated oncogenic signaling, It is likely that a combination of several pathogenic conditions is required to eventually lead to the development of lymphoma. The prevalence of B-cell lymphomas among individuals with chronic… More >

  • Open Access

    ARTICLE

    TDO2-Associated Tryptophan Metabolism Correlates with Impaired Tertiary Lymphoid Structure Maturation and Reduced B Cell Class Switching in Breast Cancer

    Weiping Yang1,#, Wei Xiao2,#, Wenhao Xu3,#, Lijun Ren1, Xian Li1, Junhua Yu1, Ronghua Wang4,*

    Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.071122 - 24 February 2026

    Abstract Background: Tertiary lymphoid structures (TLSs) promote antitumor immunity and predict favorable immunotherapy outcomes in breast cancer. The study aimed to investigate how Tryptophan 2,3-dioxygenase (TDO2)-associated tryptophan metabolism influences TLS maturation and B cell class switching in breast cancer. Methods: Bulk transcriptomic data from The Cancer Genome Atlas-Breast Invasive Carcinoma (TCGA-BRCA, n = 1055) were analyzed using Gene Set Variation Analysis (GSVA)–based metabolic scoring, immune deconvolution, and TLS quantification. Single-cell RNA sequencing (scRNA-seq, n = 26) and spatial transcriptomics (n = 1) were applied to map TDO2 expression and TLS spatial organization. Validation was performed by immunohistochemistry (nMore >

  • Open Access

    ARTICLE

    Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Chemoradiotherapy and Robotic-Assisted Resection

    Yen-Cheng Chen1,2,3, Tsung-Kun Chang1,2,4, Wei-Chih Su1,2,4, Yung-Sung Yeh4,5,6,7, Po-Jung Chen1,2, Tzu-Chieh Yin2,4,8, Ching-Chun Li2,9, Ching-Wen Huang2,3, Hsiang-Lin Tsai2,3, Jaw-Yuan Wang1,2,3,10,11,12,*

    Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.069397 - 24 February 2026

    Abstract Background: The long-term outcomes of robotic-assisted surgery and the prognostic significance of the pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced rectal cancer (LARC) remain uncertain. This study aimed to assess the long-term outcomes of patients with LARC undergoing robotic-assisted surgery and to determine the prognostic value of pretreatment NLR. Methods: We retrospectively reviewed 252 patients with LARC who were treated at a single medical center in Taiwan between January 2012 and January 2023. All patients underwent neoadjuvant concurrent chemoradiotherapy (CRT) followed by robotic-assisted surgery with total mesorectal excision (TME). Patients were stratified into four groups… More >

Displaying 1-10 on page 1 of 175. Per Page